Clinical Trial Update: Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating a single-dose fosaprepitant (MK0517) regimen for preventing chemotherapy-induced nausea and vomiting has been completed, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 3 | Status: COMPLETED | Results posted: 2010-02-12